Technical420 Site Search

Agencies across the globe continue to recognize the medical benefits associated with cannabis. It is only a matter of time before this incredible plant will be legalized in the United States.From the National Cancer Institute (NCI) to the National Institute on Drug Abuse (NIDA), the medical benefits associated with cannabis…

Insys Therapeutics, Inc. (INSY) is up more than 3% in pre-market trading after the Nasdaq-trade cannabis company reported its financial results for the second quarter, which ended on June 30th.This report comes less than a month after Insys announced that the FDA approved Syndros, an orally administered liquid formulation of…

The state of the global economy has led to a number of the best investors and economists to predict a recession within the next 12 to 18 months.As market volatility continues to increase, investors and money managers will continue to exit the stock market as they look for new investment…

After GW Pharmaceuticals (GWPH) reported overwhelmingly positive results from its first Phase 3 study on its Epidiolex product, several cannabis stocks rallied and we think this is just the start of something big.Our rationale is based off of GWPH proving that cannabis should not be labeled as Schedule I substance.…

Numbers don’t lie.Or do they?As an analyst I know they don’t lie, but they don’t always tell the whole story.Today’s tale is a perfect example.GW Pharmaceuticals (GWPH) and Insys Therapeutics, Inc. (INSY) recently reported financial results and the companies have seen opposite reactions from the market.Yesterday, INSY fell almost 3%…

What happens when you combine a hot biotech initial public offering (IPO) market with a NASDAQ traded cannabis stock focused on treatments that have a multi-billion dollar Total Addressable Market (TAM)?  Just take a look at Zynerba Pharmaceuticals (ZYNE).On August 5th, ZYNE conducted its IPO on the NASDAQ exchange and…

GW Pharmaceuticals (GWPH) and Insys Therapeutics, Inc. (INSY) reported third-quarter financial results this morning and the companies have seen opposite reactions from the market.Shares of GWPH rallied 4% off of the open, while INSY plummeted 11%. INSY has rallied off of its lows but we see further weakness ahead. Let’s highlight the results…

Investors, it is time to set aside some cash! On Wednesday, Zynerba Pharmaceuticals, Inc. (ZYNE) will have its initial public offering (IPO) on the NASDAQ exchange. Zynerba will issue 3,000,000 shares and they will be offered in the $13.00-$15.00 range. The total offering amount is $51.75 million (total expenses are…

Investors and financial institutions have shown great interest for publicly traded cannabis companies, but many are afraid to invest in them because most trade on the over-the-counter (OTC) exchange. The OTC exchange, also known as the Pink Sheets, is comprised of startups, defunct public shell companies, scams, and a few…

On Tuesday, Heather Alfonso pled guilty in United States District Court in Hartford to having received $83,000 in kickbacks from Insys Therapeutics (INSY) during January 2013 through March 2015. Alfonso said the money influenced her prescribing a particular drug, according to the United States Attorney's Office in Hartford, Connecticut.Although Insys…